EFFECT OF A CO-STIMULATORY ENDODOMAIN ON THE PERFORMANCE OF T CELLS EXPRESSING A CHIMERIC ANTIGEN RECEPTOR DIRECTED AT CD19 IN PATIENTS WITH RELAPSED/REFRACTORY B-CELL MALIGNANCIES

被引：1
|
作者：
Ramos, C. A. [1 ]
Savoldo, B. [1 ]
Liu, E. [1 ]
Bollard, C. M. [1 ]
Carrum, G. [1 ]
Kamble, R. T. [1 ]
Mims, M. P. [1 ]
Keating, M. [2 ]
Gee, A. P. [1 ]
Mei, Z. [1 ]
Rooney, C. M. [1 ]
Heslop, H. E. [1 ]
Brenner, M. K. [1 ]
Dotti, G. [1 ]
机构：
[1] Baylor Coll Med, Houston, TX 77030 USA
[2] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
来源：
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION | 2011年 / 17卷 / 02期
关键词：
D O I：
10.1016/j.bbmt.2010.12.186
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
163
引用
收藏
页码：S213 / S214
页数：2
相关论文
共 50 条
  • [21] RE: Epigenetic profiling and response to CD19 chimeric antigen receptor T-cell therapy in B-cell malignancies
    Lee, Hwan Young
    Yang, Soo-Bin
    Park, Mi Young
    Baek, Gyung Won
    Kang, Hyoung Jin
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2023, 115 (10): : 1231 - 1233
  • [22] CD19/CD20 bispecific chimeric antigen receptor (CAR) in naive/memory T-cells for the treatment of relapsed or refractory B-cell lymphomas.
    Ghafouri, Sanaz Noelle
    Walthers, Christopher
    Roshandell, Mobina
    Ji, Brenda
    Trent, Jacqueline
    Chen, Jia Ming
    Naparstek, Jacob
    Harris, Caitlin
    Schweppe, Thomas
    Nawaly, Karla K.
    Mead, Monica
    de Vos, Sven
    Young, Patricia
    Oliai, Caspian
    Schiller, Gary
    Timmerman, John M.
    Chen, Yvonne Y.
    Larson, Sarah
    CANCER RESEARCH, 2021, 81 (13)
  • [23] Factors Associated with Costs in Chimeric Antigen Receptor T-Cell Therapy for Patients with Relapsed/Refractory B-Cell Malignancies
    Zhu, Feng
    Wei, Guoqing
    Zhang, Mingming
    Zhao, Houli
    Wu, Wenjun
    Yang, Luxin
    Hu, Yongxian
    Huang, He
    CELL TRANSPLANTATION, 2020, 29
  • [24] CD19 chimeric antigen receptor-T cells as bridging therapy to allogeneic hematopoietic cell transplantation improves outcome in patients with refractory/relapsed B-cell acute lymphoblastic leukemia
    Liu, Jie
    Xu, Mengyuan
    Zhang, Xiaoqian
    Zhang, Zhuo
    Zhong, Tao
    Yu, Hongjuan
    Fu, Yueyue
    Meng, Hongbin
    Feng, Jiawei
    Zou, Xindi
    Han, Xueying
    Kang, Liqing
    Yu, Lei
    Li, Limin
    HELIYON, 2024, 10 (13)
  • [25] Infusion of chimeric antigen receptor T cells against dual targets of CD19 and B-cell maturation antigen for the treatment of refractory multiple myeloma
    Tang, Fang
    Lu, Yin
    Ge, Yongqin
    Shang, Jingjing
    Zhu, Xiaming
    JOURNAL OF INTERNATIONAL MEDICAL RESEARCH, 2020, 48 (01)
  • [26] Efficacy and safety of chimeric antigen receptor T-cell therapy targeting CD19/CD22 in refractory/relapsed transformed aggressive B-cell lymphoma
    Xu, Hao
    Lv, Qiuxia
    Huang, Liang
    Cao, Wenyue
    Wang, Jue
    Meng, Fankai
    Li, Chunrui
    Zheng, Miao
    Chen, Liting
    Mu, Ketao
    Cheng, Jiali
    Zhu, Li
    Zhou, Jianfeng
    Zhang, Yicheng
    Wang, Na
    Cao, Yang
    CYTOTHERAPY, 2023, 25 (02) : 185 - 191
  • [27] Efficacy and toxicity for CD22/CD19 chimeric antigen receptor T-cell therapy in patients with relapsed/refractory aggressive B-cell lymphoma involving the gastrointestinal tract
    Zeng, Chen
    Cheng, Jiali
    Li, Tongjuan
    Huang, Jin
    Li, Chunrui
    Jiang, Lijun
    Wang, Jue
    Chen, Liting
    Mao, Xia
    Zhu, Li
    Lou, Yaoyao
    Zhou, Jianfeng
    Zhou, Xiaoxi
    CYTOTHERAPY, 2020, 22 (03) : 166 - 171
  • [28] CHIMERIC ANTIGEN RECEPTOR MODIFIED T CELLS DIRECTED AGAINST CD19 (CTL019) INDUCE CLINICAL RESPONSES IN PATIENTS WITH RELAPSED OR REFRACTORY CD19+LYMPHOMAS
    Levine, B.
    Svoboda, J.
    Nasta, S. D.
    Porter, D.
    Chong, E.
    Lacey, S.
    Mahnke, Y.
    Melenhorst, J.
    Chew, A.
    Shah, G.
    Hasskar, J.
    Wasik, M.
    Landsburg, D.
    Mato, A.
    Garfall, A.
    Frey, N.
    Shaw, P.
    Marcucci, K.
    Shea, J.
    McConville, H.
    Manvar, N.
    O'Rourke, M.
    Lamontagne, A.
    Bersenev, A.
    Zheng, Z.
    Schuster, S.
    June, C.
    CYTOTHERAPY, 2015, 17 (06) : S13 - S13
  • [29] Phase IIa Trial of Chimeric Antigen Receptor Modified T Cells Directed Against CD19 (CTL019) in Patients with Relapsed or Refractory CD19+Lymphomas
    Schuster, Stephen J.
    Svoboda, Jakub
    Nasta, Sunita Dwivedy
    Porter, David L.
    Chong, Elise A.
    Mahnke, Yolanda
    Lacey, Simon F.
    Melenhorst, J. Joseph
    Chew, Anne
    Shah, Gaurav
    Hasskarl, Jens
    Litchman, Manuel
    Wasik, Mariusz A.
    Landsburg, Daniel J.
    Mato, Anthony R.
    Garfall, Alfred L.
    Frey, Noelle V.
    Marcucci, Katherine T.
    Shea, Joanne
    McConville, Holly
    Zheng, Zhaohui
    Levine, Bruce L.
    June, Carl H.
    BLOOD, 2014, 124 (21)
  • [30] Sustained Remissions Following Chimeric Antigen Receptor Modified T Cells Directed Against CD19 (CTL019) in Patients with Relapsed or Refractory CD19+Lymphomas
    Schuster, Stephen J.
    Svoboda, Jakub
    Nasta, Sunita Dwivedy
    Porter, David L.
    Chong, Elise A.
    Landsburg, Daniel J.
    Mato, Anthony R.
    Lacey, Simon F.
    Melenhorst, Jan J.
    Chew, Anne
    Hasskarl, Jens
    Shah, Gaurav D.
    Wasik, Mariusz A.
    Marcucci, Katherine T.
    Zheng, Zhaohui
    Levine, Bruce L.
    June, Carl H.
    BLOOD, 2015, 126 (23)
12345